The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.
 
Zev A. Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Vincent Chung
Consulting or Advisory Role - Perthera
Speakers' Bureau - AstraZeneca; Coherus Biosciences; Ipsen
Research Funding - Merck (Inst)
 
Craig E. Devoe
Honoraria - Vivacitas Oncology
Consulting or Advisory Role - Pfizer
 
Thomas J. George
Consulting or Advisory Role - BillionToOne; Seagen; Tempus
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BillionToOne (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst)
 
Esther Welkowsky
Employment - Elicio Therapeutics
Stock and Other Ownership Interests - Elicio Therapeutics
Research Funding - Elicio Therapeutics
 
Thian Kheoh
Employment - Elicio Therapeutics
Stock and Other Ownership Interests - Elicio Therapeutics
Research Funding - Elicio Therapeutics
 
Christopher M. Haqq
Employment - Elicio Therapeutics
Stock and Other Ownership Interests - Atara Biotherapeutics; Elicio Therapeutics; Johnson & Johnson; Surrozen
Research Funding - Elicio Therapeutics
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics; Elicio Therapeutics
 
Shubham Pant
Consulting or Advisory Role - AskGene Pharma; Boehringer Ingelheim; Ipsen; Janssen; Novartis; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma